GRPR and neoplasm: The effects of the [188Re]Re-DOX-liposome-BBN intravenous injection were clearly traceable with micro-SPECT/CT imaging, which demonstrated successful targeting of the GRPR in AR42J pancreatic cancer cells and significantly reduced tumor growth rate, hence increasing the mice lifespan by as much as 86.96% compared to individuals treated with [188Re]Re-liposome-BBN or liposome-DOX-BBN, whose lifespans were extended by 75% and 3.61%, respectively.